{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:15:45Z","timestamp":1789517745962,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of oncolytic viruses (OVs) for cancer treatment is emerging as a successful strategy that combines the direct, targeted killing of the cancer with the induction of a long-lasting anti-tumor immune response. Using multiple aggressive murine models of triple-negative breast cancer, we have recently demonstrated that the early administration of oncolytic Maraba virus (MRB) prior to surgical resection of the primary tumor is sufficient to minimize the metastatic burden, protect against tumor rechallenge, cure a fraction of the mice and sensitize refractory tumors to immune checkpoint blockade without the need for further treatment. Here, we apply our surgical model to other OVs: Vesicular stomatitis virus (VSV), Adenovirus (Ad), Reovirus (Reo) and Herpes simplex virus (HSV) and show that all of the tested OVs could positively change the outcome of the treated animals. The growth of the primary and secondary tumors was differently affected by the various OVs and most of the viruses conferred survival benefits in this neoadjuvant setting despite the absence of direct treatment following rechallenge. This study establishes that OV-therapy confers long-term protection when administered in the pre-operative window of opportunity.<\/jats:p>","DOI":"10.1038\/s41598-018-38385-7","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T11:05:20Z","timestamp":1549969520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Nikolas Tim","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic Guy","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Tekeste","family":"Workenhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7360-3182","authenticated-orcid":false,"given":"Diana J. M.","family":"van den Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9443-8377","authenticated-orcid":false,"given":"Rob C.","family":"Hoeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Louise","family":"Mossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9083-357X","authenticated-orcid":false,"given":"John Cameron","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Bourgeois-Daigneault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"key":"38385_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559\u201367 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"38385_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2013.220","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe, S. T. & Mossman, K. L. Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies. Mol. Ther. 22, 251\u2013256 (2014).","journal-title":"Mol. Ther."},{"key":"38385_CR3","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","volume":"72","author":"I Diaconu","year":"2012","unstructured":"Diaconu, I. et al. Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus. Cancer Res. 72, 2327\u20132338 (2012).","journal-title":"Cancer Res."},{"key":"38385_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/gt.2011.205","volume":"20","author":"OG Donnelly","year":"2013","unstructured":"Donnelly, O. G. et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 20, 7\u201315 (2013).","journal-title":"Gene Ther."},{"key":"38385_CR5","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","volume":"72","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto, S. et al. Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma. Cancer Res. 72, 2609\u20132621 (2012).","journal-title":"Cancer Res."},{"key":"38385_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/mt.2013.238","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe, S. T. et al. Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy. Mol. Ther. 22, 123\u2013131 (2014).","journal-title":"Mol. Ther."},{"key":"38385_CR7","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/mto.2016.1","volume":"3","author":"M-C Bourgeois-Daigneault","year":"2016","unstructured":"Bourgeois-Daigneault, M.-C. et al. Oncolytic vesicular stomatitis virus expressing interferon-\u03b3 has enhanced therapeutic activity. Mol. Ther. \u2014 Oncolytics 3, 16001 (2016).","journal-title":"Mol. Ther. \u2014 Oncolytics"},{"key":"38385_CR8","doi-asserted-by":"publisher","first-page":"eaao1641","DOI":"10.1126\/scitranslmed.aao1641","volume":"10","author":"M-C Bourgeois-Daigneault","year":"2018","unstructured":"Bourgeois-Daigneault, M.-C. et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci. Transl. Med. 10, eaao1641 (2018).","journal-title":"Sci. Transl. Med."},{"key":"38385_CR9","first-page":"187","volume":"11","author":"AA Alkayyal","year":"2016","unstructured":"Alkayyal, A. A., Mahmoud, A. B. & Auer, R. C. Interleukin-12-expressing oncolytic virus: A promising strategy for cancer immunotherapy. J. Taibah Univ. Med. Sci. 11, 187\u2013193 (2016).","journal-title":"J. Taibah Univ. Med. Sci."},{"key":"38385_CR10","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/mt.2008.143","volume":"16","author":"T-C Liu","year":"2008","unstructured":"Liu, T.-C., Hwang, T., Park, B.-H., Bell, J. & Kirn, D. H. The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma. Mol. Ther. 16, 1637\u20131642 (2008).","journal-title":"Mol. Ther."},{"key":"38385_CR11","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. I. et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J. Clin. Oncol. 33, 2780\u20138 (2015).","journal-title":"J. Clin. Oncol."},{"key":"38385_CR12","doi-asserted-by":"publisher","first-page":"eaam7577","DOI":"10.1126\/scitranslmed.aam7577","volume":"10","author":"A Samson","year":"2018","unstructured":"Samson, A. et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci. Transl. Med. 10, eaam7577 (2018).","journal-title":"Sci. Transl. Med."},{"key":"38385_CR13","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32 (2014).","journal-title":"Sci. Transl. Med."},{"key":"38385_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754","volume":"8","author":"Z Liu","year":"2017","unstructured":"Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S. & Bartlett, D. L. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun. 8, 14754 (2017).","journal-title":"Nat. Commun."},{"key":"38385_CR15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/mt.2014.160","volume":"22","author":"CE Engeland","year":"2014","unstructured":"Engeland, C. E. et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol. Ther. 22, 1949\u201359 (2014).","journal-title":"Mol. Ther."},{"key":"38385_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02503-8","volume":"7","author":"C-Y Chen","year":"2017","unstructured":"Chen, C.-Y. et al. Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models. Sci. Rep. 7, 2396 (2017).","journal-title":"Sci. Rep."},{"key":"38385_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1525-0016(03)00236-3","volume":"8","author":"DL Thomas","year":"2003","unstructured":"Thomas, D. L. & Fraser, N. W. HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol. Ther. 8, 543\u201351 (2003).","journal-title":"Mol. Ther."},{"key":"38385_CR18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/sj.gt.3301251","volume":"7","author":"SB Geutskens","year":"2000","unstructured":"Geutskens, S. B. et al. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther. 7, 1410\u20131416 (2000).","journal-title":"Gene Ther."},{"key":"38385_CR19","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/sj.mt.6300310","volume":"15","author":"L Chen","year":"2007","unstructured":"Chen, L. et al. Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol. Ther. 15, 2194\u2013202 (2007).","journal-title":"Mol. Ther."},{"key":"38385_CR20","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2010.103","volume":"18","author":"J Brun","year":"2010","unstructured":"Brun, J. et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol. Ther. 18, 1440\u20139 (2010).","journal-title":"Mol. Ther."},{"key":"38385_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","volume":"4","author":"DF Stojdl","year":"2003","unstructured":"Stojdl, D. F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263\u2013275 (2003).","journal-title":"Cancer Cell"},{"key":"38385_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1432-1033.1973.tb03100.x","volume":"39","author":"PA Boulanger","year":"1973","unstructured":"Boulanger, P. A. & Puvion, F. Large-scale preparation of soluble adenovirus hexon, penton and fiber antigens in highly purified form. Eur. J. Biochem. 39, 37\u201342 (1973).","journal-title":"Eur. J. Biochem."},{"key":"38385_CR23","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/gt.2008.118","volume":"15","author":"DJM van den Wollenberg","year":"2008","unstructured":"van den Wollenberg, D. J. M. et al. A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting. Gene Ther. 15, 1567\u201378 (2008).","journal-title":"Gene Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38385-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T06:02:18Z","timestamp":1671256938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38385-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["38385"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-38385-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,12]]},"assertion":[{"value":"4 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C.B. is a co-founder and on the board of directors of Turnstone Biologics which is developing oncolytic virus products.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1865"}}